Simulating Disease to Radically Transform Drug Discovery & Development
At GNS we leverage our pioneering Causal AI technology to exploit the recent explosive growth of multi-omics and clinical data to create “virtual” (in silico) patients in oncology, neurodegeneration, and immunology and reveal the hidden circuitry of disease.
We can now use Gemini in silico patients to simulate disease progression and drug response at the individual patient level to discover novel drug targets, simulate entire trials to better select patients, and rapidly generate evidence of comparative effectiveness vs other drugs.
Getting to the Why…
Meet Gemini
The in silico Patient™
Gemini – The in silico Patient™ is fueled by rich multiomics and clinical data and links drug treatment to patient characteristics to the complex genetic and molecular mechanisms and pathways driving clinical outcomes, enabling the simulation of disease progression and drug response at an individual patient level.
Gemini Solutions
Fueling Drug Discovery
Uncover novel drug targets
Discover prognostic markers
Identify best combo therapies
Accelerating Clinical Trials
Conduct head-to-head in silico trials
Reveal responding / non-responding populations & underlying mechanisms
Driving Market Access
Generate comparative effectiveness evidence
Inform line of therapy changes
Enable optimal treatment sequencing
A breakthrough approach backed by decades of research …
Coming soon
Why Causal Learning is a Superpower for Healthcare
GNS by the numbers
60+
Peer-reviewed publications
7
Of top 10 biopharmaceutical companies as customers
12
Disease-specific data partners
1010
Average number of “virtual experiments” conducted per Gemini model
Our Partners & Customers
